

REMARKS

Claims 1 and 4 have been amended. Claims 2 and 3 have been cancelled. Claims 5 and 6 have been newly added. Thus, claims 1, 4, 5, and 6 are in the application, and stand ready for action on the merits.

Support for the concept of atomoxetine or a compound of formula I as sole active agent (Claim 1) can be found in the specification as originally filed at, for example, page 58, line 22; page 60, lines 14-15 and 17; and in Tables 1 and 2 at pages 61-62.

Support for the concept of atomoxetine hydrochloride (Claim 4) can be found in the specification as originally filed at, for example, page 15, lines 15-16, and in Tables 1 and 2 at pages 61-62, respectively.


Support for the concept of attention-deficit/hyperactivity disorder comorbid with a Pervasive Developmental Disorder (Claims 5 and 6) can be found in the specification as originally filed at, for example, page 14, lines 11-23.

As none of the present amendments introduces any new matter into the application, entry thereof is believed to be in order, and is respectfully requested.

Examination of the present application and allowance of claims 1, 4, 5, and 6 at an early date is earnestly solicited.

If the Examiner has any questions, or would like to discuss any matters in connection with the present application, s/he is invited to contact the undersigned at (317) 433-4983.

Respectfully submitted,



Charles E. Cohen, Ph.D.
Attorney for Applicants
Registration No. 34,565
Phone: 317-433-4983

Eli Lilly and Company
Patent Division
P.O. Box 6288
Indianapolis, Indiana 46206-6288

February 7, 2006